Matching Placebo to Ustekinumab

Phase 3

Matching Placebo to Ustekinumab is one of 9 therapeutic programs targeting Plaque Psoriasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Plaque PsoriasisActive, not recruiting

Plaque PsoriasisPhase 3

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Plaque Psoriasis

#DrugCompanyPhaseTrials

Otezla

Amgen

Phase 3

4 2

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

5 3

JNJ-77242113

Johnson & Johnson

Phase 3

5 4

Envudeucitinib

AAlumis Inc

Phase 3

3 5

Matching Placebo to Ustekinumab

Johnson & Johnson

Phase 3

1 6

ORKA-002

OOruka Therapeutics, Inc.

Phase 2

1 7

ESK-001

AAlumis Inc

Phase 2

3 8

ORKA-001

OOruka Therapeutics, Inc.

Phase 2

3 9

ZP9830

Zealand Pharma

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Plaque Psoriasis

NCT06934226

Clinical

Trials by Indication[1]

Plaque Psoriasis1 trial

77242113PSO3006: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ 77242113 for the Treatment of Participants With Moderate to Severe Plaque Ps

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06934226·752 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Matching Placebo to Ustekinumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Matching Placebo to Ustekinumab. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Matching Placebo to Ustekinumab

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Plaque Psoriasis1 trial

References

Drug Info

Quick Facts

Related News